Symptomatic | Total | Cepheid + | Cepheid − | Sofia + | Sofia − |
---|---|---|---|---|---|
(A) Symptomatic | |||||
n | 148 | 41 | 107 | 36 | 112 |
Average age, yrs (range) | 44.1 (18–83) | 46.3 (18–83) | 43.3 (20–76) | 47.2 (20–83) | 43.2 (18–76) |
Sex, male | 42 (28.4%) | 21 (51.2%) | 21 (19.6%) | 18 (50%) | 24 (21.4%) |
Symptoms | |||||
Fever | 29 (19%) | 15 (36.6%) | 14 (13.1%) | 11 (30.6%) | 18 (16.1%) |
Cough | 76 (51.3%) | 26 (63.4%) | 50 (46.7%) | 22 (61.1%) | 54 (48.2%) |
Congestion | 77 (52.0%) | 26 (63.4%) | 51 (47.6%) | 24 (66.7%) | 53 (47.3%) |
Shortness of breath | 14 (9.5%) | 4 (9.8%) | 10 (9.3%) | 4 (11.1%) | 10 (8.9%) |
Headache | 45 (30.4%) | 11 (26.8%) | 34 (31.8%) | 10 (27.8%) | 35 (31.3%) |
Sore throat | 49 (33.1%) | 9 (22.0%) | 40 (37.4%) | 8 (22.2%) | 41 (36.6%) |
Loss of taste | 17 (11.5%) | 10 (24.4%) | 7 (6.5%) | 9 (25.0%) | 8 (7.1%) |
Loss of smell | 18 (12.2%) | 10 (24.4%) | 8 (7.5%) | 9 (25.0%) | 9 (8.0%) |
Abdominal pain | 5 (3.4%) | 1 (2.4%) | 4 (3.7%) | 1 (2.8%) | 4 (3.6%) |
Nausea | 12 (8.1%) | 6 (14.6%) | 6 (5.6%) | 5 (13.9%) | 7 (6.3%) |
Vomiting | 8 (5.4%) | 2 (4.9%) | 6 (5.6%) | 2 (5.6%) | 6 (5.4%) |
Diarrhea | 14 (9.5%) | 3 (7.3%) | 11 (10.3%) | 3 (8.3%) | 11 (9.8%) |
Myalgia | 32 (21.6%) | 9 (22.0%) | 23 (21.5%) | 9 (25.0%) | 23 (20.5%) |
Fatigue | 31 (20.9%) | 6 (14.6%) | 25 (23.3%) | 4 (11.1%) | 27 (24.1%) |
Other (Chills) | 24 (16.2%) | 9 (22.0%) | 15 (14.0%) | 9 (25.0%) | 15 (13.4%) |
Total number of symptoms, average (range) | 3.0 (1–7) | 3.6 (1–7) | 2.8 (1–7) | 3.6 (1–7) | 2.9 (1–7) |
No. days of symptoms prior to test, average (range) | 3.6 (1–7) | 3.8 (1–7) | 3.5 (1–7) | 3.7 (2–7) | 3.6 (1–7) |
Known exposure | 31 (20.9%) | 12 (29.3%) | 19 (17.7%) | 11 (30.6%) | 20 (17.9%) |
No. days post-exposure until test, average (range) | 5.3 (1–12) | 4.8 ( 1–7) | 5.8 (1–12) | 5.1 (1–7) | 5.5 (1–12) |
Asymptomatic | Total | Cepheid + | Cepheid − | Sofia + | Sofia − |
---|---|---|---|---|---|
(B) Asymptomatic. | |||||
n | 144 | 6 | 138 | 2 | 142 |
Average age, years (range) | 38.6 (17–80) | 46.7 (28–68) | 38.2 (17–80) | 50.5 (34–67) | 38.8(17–80) |
Sex, male* | 51 (41.1%) | 2 (33.3%) | 49 (41.5%) | 1 (50.0%) | 50 (41.0%) |
Reason for testing | |||||
Exposure | 8 (5.6%) | 2 (33.3%) | 6 (4.3%) | 0 (0%) | 8 (5.6%) |
Required for work | 3 (2.1%) | 1 (16.7%) | 2 (1.4%) | 0 (0%) | 3 (2.1%) |
Required for travel/Re-entry | 10 (6.9%) | 0 (0%) | 10 (7.2%) | 0 (0%) | 10 (7.0%) |
Required for procedure | 33 (22.9%) | 1 (16.7%) | 32 (23.2%) | 1 (50%) | 32 (22.5%) |
Asymptomatic Surveillance | 47 (32.6%) | 0 (0%) | 47 (34.1%) | 0 (0%) | 47 (33.1%) |
Unknown | 43 (29.9%) | 2 (33.3%) | 41 (29.7%) | 1 (50%) | 42 (29.6%) |
Known exposure | 7 (4.9%) | 2 (33.3%) | 5 (3.6%) | 0 (0%) | 7 (5.0%) |
No. days post-exposure to test, average (range) | 3.4 (1–7) | 2.5 (1–4) | 4.0 (1–7) | N/A | 3.4 (1–7) |